- Featured Product
- KD/KO Validated
VIRMA/KIAA1429 Polyklonaler Antikörper
VIRMA/KIAA1429 Polyklonal Antikörper für WB, IHC, IF/ICC, Indirect ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus
Anwendung
WB, IHC, IF/ICC, Indirect ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 30166-1-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
30166-1-PBS bindet in WB, IHC, IF/ICC, Indirect ELISA VIRMA/KIAA1429 und zeigt Reaktivität mit human, Maus
| Getestete Reaktivität | human, Maus |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | VIRMA/KIAA1429 fusion protein Ag32830 |
| Vollständiger Name | KIAA1429 |
| Beobachtetes Molekulargewicht | 200-210 kDa |
| GenBank-Zugangsnummer | BC003701 |
| Gene symbol | KIAA1429 |
| Gene ID (NCBI) | 25962 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS only |
| Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
VIRMA (KIAA1429) is a key component of m6A methyltransferase (writer) complex that include METTL3, METTL14, WTAP, VIRMA, HAKAI, ZC3H13, and RBM15. VIRMA mediates methylation in the 3'UTR and around the stop codon, thus affecting alternative polyadenylation. VIRMA has been reported to act as an oncogenic factor in breast cancer and liver cancer. KIAA1429 exhibits differential nuclear and cytoplasmic distribution in colorectal cancer samples, and high cytoplasmic expression of KIAA1429 is associated with poor response to chemotherapy. BRAF-mediated phosphorylation of KIAA1429 facilitates its aggregation in the cytoplasm. Furthermore, cytoplasmic KIAA1429 promotes WNT pathway activation by binding and stabilizing FZD7, thereby further enhancing cancer stemness and oxaliplatin resistance (PMID: 40611274). Moreover, this antibody can not recognize short isoforms.







